Page 2 - Bridging Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Christine and i got was based off of the original strain. it wasn't based off of omicron. which one will the kids get? >> i believe again we don't do science by press release, so the data is not all out, but i believe that it is based on the ancestral strain. so we'll see as it comes out. >> and moderna says that the vaccine shows a favorable safety profile but the efficacy rate is not high. why is it it worth getting kidsx natured is the likelihood of they willing ill is low? >> well, we know that children are not supposed to die so any layers of protection that we can offer this study was a ...

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

That -- that the bridging study that move forward on the authorization had only about 2,000 kids. so, we are going to collect a lot more information hopefully in the coming months. >> dr. wen, according to the american academy of pediatrics, almost 118,000 children tested positive for covid last week. as much as the country moves into colder months, cold or flu season, how big of a difference will getting younger -- the younger population vaccinated, how much difference will that actually make? >> i think it will make a difference in terms of where covid-19 goes because we could have 28 millio...

Sometimes, requiring hospitalization. so, but the -- but the key point to remember, anderson, is that the rate of myocarditis and other cardiac sequelae from the virus, is possibly as high as 450 per -- per million. so, not only that, we are also talking about other cardiovascular consequences. thrombotic events, strokes. so, all of that has to be kept in mind, as well. so, myocarditis is still an extremely rare event. it is something that we are going to have to watch, and as dr. wen points out, this study that -- that the bridging study that move forward on the authorization had only about 2...